Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor

被引:1
|
作者
Rakotoambinina, B
Médioni, J
Rabian, C
Jubault, V
Jais, JP
Viard, JP
机构
[1] Hop Necker Enfants Malad, Serv Immunol Clin, F-75743 Paris 15, France
[2] Hop Necker Enfants Malad, Dept Biostat, F-75743 Paris 15, France
关键词
lipodystrophy; protease inhibitors; nucleoside analogs; hyperlipidemia; HIV infection;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To assess the frequency and features of lipodystrophic syndromes in HIV-1-infected patients receiving highly active antiretroviral therapy (HAART) with a protease inhibitor (PI), and examine whether clinical and biologic abnormalities are always associated in these conditions. Methods: Retrospective-prospective single-center observational study of 175 patients. Comparisons for continuous variables by t-test and paired t-test, and Kaplan-Meier analysis of time to onset of lipodystrophy were performed. Results: In all, 51 patients (29%) had morphologic changes, after a mean HAART duration of 20.0 +/- 6.1 months, and were categorized into pure lipoatrophy (n = 16), mixed syndrome (truncal fat accumulation and face or limb lipoatrophy) (n = 30) or pure truncal fat accumulation (In = 5). Because of the small number, the latter group was not analyzed statistically. No differences were found among patients with lipoatrophy, mixed syndrome, or no lipodystrophy, in terms of gender, CD4 count, and HIV RNA plasma load at time of HAART initiation, nor in response to treatment. Patients with a mixed syndrome were older. Patients with lipoatrophy had longer duration of HIV disease, pre-HAART exposure to nucleoside analog therapy, and HAART. Baseline and pre-HAART fasting triglyceride levels were higher in patients who developed lipoatrophy, whereas weight and fasting cholesterol were higher in patients who developed a mixed syndrome. After 12 and 24 months on HAART, triglycerides and cholesterol rose significantly in all patients, independently of lipodystrophy, whereas these parameters were not increased during nucleoside analog therapy. Conclusions: Nucleoside analog exposure appears as a risk factor for lipoatrophy. Age and nutritional status (reflected by baseline weight, triglycerides and cholesterol) may influence the evolution to lipoatrophy or a mixed syndrome. Hyperlipidemia is observed in the absence of lipodystrophy and depends on PI exposure.
引用
收藏
页码:443 / 449
页数:7
相关论文
共 50 条
  • [1] Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia
    Lu, Ching-Lan
    Lin, Yu-Hui
    Wong, Wing-Wai
    Lin, Hsi-Hsin
    Ho, Mao-Wang
    Wang, Ning-Chi
    Hsieh, Szu-Min
    Sheng, Wang-Huei
    Hung, Chien-Ching
    Chen, Mao-Yuan
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2011, 44 (04) : 258 - 264
  • [2] Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy
    Calza, L
    Manfredi, R
    Farneti, B
    Chiodo, F
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 (01) : 54 - 59
  • [3] No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy
    Calza, L.
    Colangeli, V.
    Magistrelli, E.
    Manfredi, R.
    Bon, I.
    Re, M. C.
    Viale, P.
    HIV MEDICINE, 2016, 17 (08) : 631 - 633
  • [4] Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy
    Koppel, K
    Bratt, G
    Schulman, S
    Bylund, H
    Sandström, E
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 29 (05) : 441 - 449
  • [5] Protease gene polymorphism in HIV-1-infected patients and response to therapy including a protease inhibitor.
    Mouroux, M
    Bossi, P
    Yvon-Groussin, A
    Delaugerre, C
    Valantin, MA
    Tubiana, R
    Coutellier, A
    Bonmarchand, M
    Bricaire, F
    Katlama, C
    Agut, H
    Huraux, JM
    Calvez, V
    PATHOLOGIE BIOLOGIE, 1999, 47 (05): : 549 - 552
  • [6] A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
    van Leeuwen, R
    Katlama, C
    Murphy, RL
    Squires, K
    Gatell, J
    Horban, A
    Clotet, B
    Staszewski, S
    van Eeden, A
    Clumeck, N
    Moroni, M
    Pavia, AT
    Schmidt, RE
    Gonzalez-Lahoz, J
    Montaner, J
    Antunes, F
    Gulick, R
    Bánhegyi, D
    van der Valk, M
    Reiss, P
    van Weert, L
    van Leth, F
    Johnson, VA
    Sommadossi, JP
    Lange, JMA
    AIDS, 2003, 17 (07) : 987 - 999
  • [7] Associations of antiretroviral therapy and comorbidities with neurocognitive outcomes in HIV-1-infected patients
    Siangphoe, Uma
    Archer, Kellie J.
    Nguyen, Christopher
    Lee, Kwan R.
    AIDS, 2020, 34 (06) : 893 - 902
  • [8] Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy
    Dola, Chi P.
    Khan, Rubina
    DeNicola, Nathaniel
    Amirgholami, Mahin
    Benjamin, Tara
    Bhuiyan, Azad
    Longo, Sherri
    JOURNAL OF PERINATAL MEDICINE, 2012, 40 (01) : 51 - 55
  • [9] Predictors of viral load response in triple therapy with protease inhibitor in HIV infected patients
    Frottier, J
    Meynard, JL
    Morand-Joubert, L
    Guiguet, M
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 1998, 182 (05): : 981 - 992
  • [10] Monitoring of lipodystrophic and metabolic abnormalities in HIV-1 infected children on antiretroviral therapy
    Spoulou, Vana
    Kanaka-Gantenbein, Christina
    Bathrellou, Irini
    Mora, Stefano
    Mostrou, Glyceria
    Sidossis, Lambros
    Chrousos, George
    Theodoridou, Maria
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2011, 10 (02): : 149 - 155